Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Poor Performance Status
100%
Treatment Strategy
100%
Comorbidity
66%
Chemotherapy
66%
Non-small Cell Lung Cancer (NSCLC)
66%
Combination Chemotherapy
66%
Treatment Options
33%
Performance Status
33%
Gemcitabine
33%
Disease Burden
33%
Optimal Treatment
33%
Lung Cancer
33%
Paclitaxel
33%
Novel Agents
33%
Phase II Trial
33%
Prospective Clinical Trial
33%
Heterogeneous Groups
33%
Potential Toxicity
33%
Single-agent Chemotherapy
33%
Eastern Cooperative Oncology Group
33%
Epidermal Growth Factor Receptor Inhibitors
33%
Chemotherapy Agents
33%
Best Medical Treatment
33%
Adverse Reactions
33%
Pemetrexed
33%
Docetaxel
33%
Disease Symptoms
33%
Selective Targeting
33%
Vinorelbine
33%
Paclitaxel Poliglumex
33%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Combination Chemotherapy
40%
Comorbidity
40%
Lung Cancer
20%
Clinical Trial
20%
Adverse Event
20%
Disease Burden
20%
Paclitaxel
20%
Oncology
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Gemcitabine
20%
Docetaxel
20%
Case History
20%
Chemotherapy Agent
20%
Pemetrexed
20%
Vinorelbine
20%
Paclitaxel Poliglumex
20%
Diseases
20%
Phase III Trials
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Chemotherapy
80%
Comorbidity
40%
Diseases
40%
Clinical Trial
20%
Adverse Event
20%
Lung Cancer
20%
Paclitaxel
20%
Chemotherapy Agent
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Gemcitabine
20%
Pemetrexed
20%
Docetaxel
20%
Vinorelbine
20%
Paclitaxel Poliglumex
20%
Phase III Trials
20%
Nursing and Health Professions
Non Small Cell Lung Cancer
100%
Combination Chemotherapy
40%
Comorbidity
40%
Disease Burden
20%
Lung Cancer
20%
Adverse Event
20%
Paclitaxel
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Pemetrexed
20%
Docetaxel
20%
Gemcitabine
20%
Vinorelbine Tartrate
20%
Paclitaxel Poliglumex
20%
Diseases
20%